About UK AML Research Network

The UK Acute Myeloid Leukaemia Research Network (UK AMLRN) is an autonomous UK research grouping whose aim is to deliver clinical studies and linked translational science with the aim of improving the outcomes of patients with AML. Recognising the importance of prospective trials in generating practice informing data a major focus for the UK AMLRN over more than four decades has been the design and delivery of randomised trials of new therapeutic strategies. These trials have has also provided a highly effective vehicle for pioneering work evaluating genomics and MRD as both prognostic and predictive biomarkers in patients treated with intensive chemotherapy. In partnership with the IMPACT transplant trial network the UK AMLRN has more recently played a pivotal role in the prospective evaluation of transplant interventions in AML. More than 1,000 patients have been randomised to trials examining innovative therapeutic strategies designed to improve the outcome of patients allografted for AML making the UK AMLRN one of the largest AML transplant cooperative groups in the world.

International partnership continues to play a central role in the work of the UK AMLRN. In collaboration with HOVON and the AMLSG, the UK AMLRN is currently playing a central role in the evaluation of targeted therapies in older patients with AML in the EVOLVE trial portfolio. Additional collaborations with US groups, notably the MD Anderson Cancer Centre are focusing on evaluation of the role of venetoclax based regimens in fit adults with AML. A more recent priority has been the establishment of a platform trial in relapsed AML building on a productive collaboration with the INTERCEPT trial led by the Australian ALLG group. In 2025, recognising the emerging importance of real world data, the MyeCare Registry, was launched. MyeCare’s integration of prospective data generated on newly diagnosed and relapsed adults with the results of whole genome sequencing will generate a globally significant dataset and provide important insights into disease biology, equity of access to innovative therapies and transplant as well as supporting translational science.

Central to the delivery of this broad trial portfolio has been partnership with a number of excellent University Trials Units and, more recently ACT, the UK’s first academic CRO. ACT’s funding of the Trials Acceleration Programme and IMPACT transplant trials networks and its ability to generate registration standard data integrated with the translational outputs from the Trials Acceleration Laboratory and the work of other world class UK translational laboratories is now attracting increasing numbers of registration standard trials from the global pharmaceutical sector to the UK.

The UK AMLRN hosts an annual AML Academy over two days every September. The AML Academy is open to all members of the UK clinical AML community and attracts an international faculty. Trainee engagement is of central importance to the UK AMLRN which works with the recently established UK BCRN to support the development of cross-cutting initiatives with other UK haemato-oncology disease specific groups. Key amongst these are innovative strategies to optimise patient and public engagement in clinical trial design and delivery.